Back to Stakeholders

The German Federal Ministry of Education and Research (BMBF) is the pioneering Western government funder of large-scale psychedelic clinical trials, having provided approximately €5 million to the EPIsoDE study — the first government-funded Phase 2 psilocybin trial for treatment-resistant major depression — conducted at the Central Institute for Mental Health in Mannheim and Charité Berlin. Germany subsequently became the first EU country to establish a psilocybin compassionate access program for treatment-resistant depression.

Foundations & Philanthropy Snapshot

Grant-Making Organizations

Classification

Grant Program (Host Organization)

Geography

Global

Coverage

Global

Last Verified

Apr 10, 2026

Funding Focus Areas

Academic Research FundingClinical Trial Funding

Support Types

Grant FundingProgrammatic Sponsorship

Philanthropy Notes

Auto-backfilled baseline philanthropy profile from existing category tags and website. Manual enrichment recommended for recipient-level details.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Verification Notes

Verified against official BMBF research funding pages.

Primary Funding Link

Quick Facts

Type
Other
HQ
Germany
Website
Visit

Collaborated Trials

1